比较[177Lu]Lu-PSMA-X与紫杉烷化疗在未接受紫杉烷化疗的转移性去势抵抗性前列腺癌患者中的疗效:系统综述与Meta分析
该系统综述与Meta分析检索至2024年3月的文献,纳入24项[177Lu]Lu-PSMA-X治疗研究和17项紫杉烷治疗研究,比较未接受过紫杉烷化疗的mCRPC患者的PSA50缓解率。结果显示两组PSA50缓解率相当,尽管研究间异质性较大,且未接受紫杉烷组治疗前暴露更广泛。作者认为[177Lu]Lu-PSMA-X RLT可能用于不能或选择不接受化疗的未接受紫杉烷患者。
要点
- 未接受紫杉烷的mCRPC患者中,[177Lu]Lu-PSMA-X RLT与紫杉烷化疗的PSA50缓解率相当。
- 未接受紫杉烷组治疗前暴露更广泛,研究间存在较大异质性。
- 作者认为[177Lu]Lu-PSMA-X RLT可能用于不能或选择不接受化疗的未接受紫杉烷患者。
核心结论
- 该Meta分析合并了未接受紫杉烷的mCRPC患者接受[177Lu]Lu-PSMA-X RLT与紫杉烷治疗的最大队列,强调两组PSA50缓解率相似。
- 作者认为[177Lu]Lu-PSMA-X RLT可能用于不能或选择不接受化疗的未接受紫杉烷患者。
研究设计与样本
- 系统综述与Meta分析,检索多个文献数据库,纳入截至2024年3月发表的文献。
- 从2019年至2023年发表的8414项研究中,最终纳入[177Lu]Lu-PSMA-X治疗组24项研究和紫杉烷治疗组17项研究。
- 终点包括前列腺特异性抗原(PSA)缓解率(RR)、无进展生存期和总生存期,在可行时合并个体患者数据。
- PSA50定义为血清PSA较基线下降至少50%的患者比例的中位数,对PSA50缓解率进行比例Meta分析,生成合并估计值和95%置信区间(95%CI)。
主要发现
- 未接受紫杉烷的患者接受[177Lu]Lu-PSMA-X RLT与接受紫杉烷化疗相比,PSA50缓解率相当,尽管研究间异质性较大。
- 未接受紫杉烷组治疗前暴露更广泛。
关键数值与推荐
- PSA50定义为血清PSA较基线下降至少50%的患者比例的中位数。
- 对PSA50缓解率进行比例Meta分析,生成合并估计值和95%CI。
临床怎么用
- 作者认为[177Lu]Lu-PSMA-X RLT可能用于不能或选择不接受化疗的未接受紫杉烷患者。
局限性
- 研究间存在较大异质性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION AND AIM: Radioligand therapy (RLT) with 177Lu-labelled prostate specific membrane antigen ([177Lu]Lu-PSMA-X, referring with "PSMA-X" to a generic PSMA chemical compound) inhibitors has emerged as a viable treatment option in metastatic castration resistant prostate cancer patients having previously progressed on taxane and androgen receptor inhibitors. The aim of this study was to perform a systematic review and meta-analysis to assess the therapeutic efficacy of [177Lu]Lu-PSMA-X compared to taxane chemotherapy in taxane-chemo-naïve patients with metastatic castration-resistant prostate cancer. MATERIALS AND METHODS: Searches in several bibliographic databases were made using relevant key words, and articles published up to March 2024 were included. The endpoints included prostate specific antigen (PSA) response rate (RR), progression-free survival, and overall survival. Individual patient data were pooled when feasible. PSA50 was defined as the median proportion of patients achieving at least a 50% decline in serum PSA from baseline. A meta-analysis of the PSA50 response rate (proportion meta-analysis) was performed, generating pooled estimates and 95% confidence intervals (95% CI). RESULTS: From the initially selected 8,414 studies published between 2019 and 2023, 24 were included in the [177Lu]Lu-PSMA-X treated group and 17 in the taxane treated group. Our findings show that [177Lu]Lu-PSMA-X RLT yielded comparable PSA50 responses in taxane-naïve patients versus those receiving taxane chemotherapy, despite considerable study heterogeneity. Notably, the taxane-naïve group had more extensive pretreatment. CONCLUSIONS: This meta-analysis combines the largest cohorts of taxane-naïve mCRPC patients treated with [177Lu]Lu-PSMA-X RLT and taxane-treated mCRPC. It underscores similar PSA50 response rates in both groups, suggesting a potential role for [177Lu]Lu-PSMA-X RLT in taxane-naïve patients who cannot or choose not to undergo chemotherapy.
引用
- Almeida LS, García Megías I, Etchebehere ECSC, et al. Assessment of the therapeutic efficacy of [177Lu]Lu-PSMA-X compared to taxane chemotherapy in taxane-chemo-naïve patients with metastatic castration-resistant prostate cancer: A systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2024. PMID: 39453485. doi:10.1007/s00259-024-06932-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。